SAREPTA THERAPEUTICS INC's ticker is and the CUSIP is 803607AB6. A total of 25 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $291,564 | +4.5% | 150,000 | 0.0% | 0.00% | – |
| Q4 2022 | $279,047 | +10.7% | 150,000 | 0.0% | 0.00% | – |
| Q3 2022 | $252,000 | -93.9% | 150,000 | -95.4% | 0.00% | -100.0% |
| Q2 2022 | $4,108,000 | -37.1% | 3,250,000 | -35.0% | 0.01% | -30.0% |
| Q1 2022 | $6,535,000 | +62.1% | 5,000,000 | +81.8% | 0.01% | +66.7% |
| Q4 2021 | $4,031,000 | -50.3% | 2,750,000 | -50.0% | 0.01% | -53.8% |
| Q3 2021 | $8,116,000 | +206.6% | 5,500,000 | +175.0% | 0.01% | +225.0% |
| Q2 2021 | $2,647,000 | +1.3% | 2,000,000 | 0.0% | 0.00% | -20.0% |
| Q1 2021 | $2,613,000 | +325.6% | 2,000,000 | +700.0% | 0.01% | +400.0% |
| Q4 2020 | $614,000 | -60.4% | 250,000 | -66.7% | 0.00% | -75.0% |
| Q3 2020 | $1,551,000 | +169.3% | 750,000 | +200.0% | 0.00% | +100.0% |
| Q2 2020 | $576,000 | -23.7% | 250,000 | -50.0% | 0.00% | -33.3% |
| Q1 2020 | $755,000 | -61.7% | 500,000 | -66.7% | 0.00% | -50.0% |
| Q3 2019 | $1,972,000 | – | 1,500,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DeepCurrents Investment Group LLC | 82,499,000 | $120,618,000 | 3.75% |
| WOLVERINE ASSET MANAGEMENT LLC | 76,497,000 | $112,118,000 | 1.04% |
| Verition Fund Management LLC | 24,689,000 | $36,219,000 | 0.26% |
| Baker Brothers Advisors | 29,174,000 | $42,695,000 | 0.21% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 6,858,000 | $10,032,000 | 0.17% |
| LORD, ABBETT & CO. LLC | 48,435,000 | $71,054,000 | 0.16% |
| Calamos Advisors LLC | 21,131,000 | $30,817,000 | 0.12% |
| PALISADE CAPITAL MANAGEMENT, LP | 3,218,000 | $4,726,000 | 0.10% |
| Point72 Asset Management, L.P. | 9,507,000 | $13,948,000 | 0.06% |
| BALYASNY ASSET MANAGEMENT L.P. | 10,000,000 | $14,609,000 | 0.05% |